NIP
BBIO icon

Nicholas Investment Partners’s BridgeBio Pharma BBIO Stock Holding History

Nicholas Investment Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.2M Buy
311,494
+12,585
+4% +$881K 1.31% 12
2026
Q1 		$22.2M Buy
298,909
+14,227
+5% +$1.03M 1.6% 8
2025
Q4 		$21.8M Buy
284,682
+13,052
+5% +$857K 1.59% 8
2025
Q3 		$14.1M Buy
271,630
+112,129
+70% +$5.47M 1.08% 18
2025
Q2 		$6.89M Sell
159,501
-7,154
-4% -$260K 0.61% 54
2025
Q1 		$5.76M Buy
166,655
+106,763
+178% +$3.6M 0.59% 58
2024
Q4 		$1.64M Buy
59,892
+24,248
+68% +$627K 0.14% 165
2024
Q3 		$907K Buy
+35,644
New +$936K 0.08% 190
2022
Q1 		– Sell
-294,879
Closed -$4.92M – 193
2021
Q4 		$4.92M Buy
294,879
+8,747
+3% +$370K 0.31% 111
2021
Q3 		$13.4M Sell
286,132
-165,850
-37% -$8.89M 0.98% 29
2021
Q2 		$27.6M Sell
451,982
-37,641
-8% -$2.15M 1.73% 2
2021
Q1 		$30.2M Buy
489,623
+77,852
+19% +$5.09M 2.1% 2
2020
Q4 		$29.3M Buy
411,771
+118,789
+41% +$5.73M 2.26% 2
2020
Q3 		$11M Buy
292,982
+239,626
+449% +$7.54M 1.19% 28
2020
Q2 		$1.74M Sell
53,356
-7,068
-12% -$215K 0.35% 109
2020
Q1 		$1.75M Buy
60,424
+40,615
+205% +$1.26M 0.34% 116
2019
Q4 		$694K Buy
19,809
+9,624
+94% +$267K 0.07% 192
2019
Q3 		$219K Buy
+10,185
New +$282K 0.02% 198

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Nicholas Investment Partners's BBIO Position: Q2 2026 in Review

Nicholas Investment Partners increased its BridgeBio Pharma (BBIO) stake by 4.2% in Q2 2026, buying an estimated $881K and bringing the position to 311,494 shares worth $23.2M. The position accounts for 1.31% of the portfolio, ranked #12.

Nicholas Investment Partners first reported a position in BBIO in Q3 2019 and has held it in 18 quarters since. The position peaked at $30.2M in Q1 2021. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Nicholas Investment Partners held 311,494 shares of BridgeBio Pharma worth $23.2M as of Q2 2026.
  • Nicholas Investment Partners bought 12,585 BridgeBio Pharma shares in Q2 2026, an estimated $881K.
  • BridgeBio Pharma made up 1.31% of Nicholas Investment Partners's portfolio in Q2 2026, its #12 holding.
  • Nicholas Investment Partners first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 18 quarters since.
  • Nicholas Investment Partners's BridgeBio Pharma position peaked at $30.2M in Q1 2021.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Nicholas Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.